NEJM This Week

This week, we present new research on treatment for muscle-invasive bladder cancer, left atrial appendage closure versus medical therapy for atrial fibrillation, gene-editing approaches for sickle cell disease and β-thalassemia, and the safety of discontinuing beta-blockers after myocardial infarction. We also review GLP-1 receptor agonists and discuss a Clinical Problem-Solving case of a man with progressive confusion. Perspectives explore corporatization; biologic, as opposed to chronologic, aging; and a legal case that could affect mental-health policy.

This week, we present new clinical trials on immunotherapy for stage III mismatch repair–deficient colon cancer, early surgery for asymptomatic aortic stenosis, an approach to dengue virus suppression, and advances in gene and prime-editing therapies for rare disorders. We also review minipuberty. We follow the case of a 12-year-old girl with altered mental status and persistent hypoglycemia, and we explore Perspectives on corporate influences on health, vaccine communication, antitrust policy, conflicts of interest, and the meaning of the number needed to treat.

This week, we explore new evidence comparing oral anticoagulants for acute venous thromboembolism, treatment for chemotherapy-induced thrombocytopenia, and early results of gene therapy for inherited deafness. We also examine evolving strategies for chronic lymphocytic leukemia, review the management of polymyalgia rheumatica, and present a case discussion of a woman with chest pain, dyspnea, and syncope. We explore gastric cancer prevention, competency-based billing, the health consequences of immigration enforcement, access to high-cost gene therapies, and we present a Perspective on good compressions.

This week, we explore a phase 3 trial of finerenone in type 1 diabetes and chronic kidney disease and guidance on timing of nonculprit-lesion PCI after STEMI. We cover an investigational therapy for Dravet syndrome and neoadjuvant treatment for high-risk intrahepatic cholangiocarcinoma. We review the effects of radiotherapy on normal tissue, a puzzling case of progressive neurologic decline after suspected foodborne illness, and Perspectives on private equity, the AHEAD model, and medical credit cards.

This week, we explore a new standard of care for high-risk HER2-positive early breast cancer, long-acting therapy for people with HIV facing adherence challenges, a first-in-class trial of a p53 reactivator, and tecovirimat for mpox. We review group B streptococcal disease and a revealing case of prosthetic joint infection. Perspectives examine the role of folate therapy, Medicare drug-price negotiation, AI in medical education, and incidental findings.